Kedudukan dalam Saham
#25179
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to... Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.
Harga Saham
$1.95
Disegerakkan terakhir: 2022-07-29
Perubahan (1 tahun)
0.00%
Perdagangan Cortexyme, Inc. (CRTX)
Harga CRTX dengan permodalan pasaran b
Modal pasaran bagi Cortexyme, Inc.(CRTX)
Modal Pasaran: $52.48M
Sehingga August 2026, Cortexyme, Inc. mempunyai modal pasaran sebanyak $52.48M. Ini menjadikan Cortexyme, Inc. syarikat ke-25179th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Cortexyme, Inc. dari 2019 hingga 2026
CRTX berbanding dengan 5 teratas yang paling popular stocks
| Harga CRTX |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.257T
|
+10,017,403.34%
|
|
|
|
|
$4.599T
|
+8,763,132.61%
|
|
|
|
|
$4.107T
|
+7,825,441.76%
|
|
|
|
|
$3.577T
|
+6,816,746.16%
|
|
|
|
|
$2.807T
|
+5,349,526.26%
|
